Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash to Debt 0.81
ARIA's Cash to Debt is ranked lower than
82% of the 830 Companies
in the Global Biotechnology industry.

( Industry Median: 56.40 vs. ARIA: 0.81 )
ARIA' s 10-Year Cash to Debt Range
Min: 0.8   Max: 24.17
Current: 0.81

0.8
24.17
Equity to Asset 0.07
ARIA's Equity to Asset is ranked lower than
91% of the 600 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. ARIA: 0.07 )
ARIA' s 10-Year Equity to Asset Range
Min: -2.2   Max: 0.89
Current: 0.07

-2.2
0.89
F-Score: 5
Z-Score: -1.30
M-Score: -2.46
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -136.23
ARIA's Operating margin (%) is ranked lower than
57% of the 649 Companies
in the Global Biotechnology industry.

( Industry Median: -75.73 vs. ARIA: -136.23 )
ARIA' s 10-Year Operating margin (%) Range
Min: -526300   Max: 58.61
Current: -136.23

-526300
58.61
Net-margin (%) -140.67
ARIA's Net-margin (%) is ranked lower than
59% of the 649 Companies
in the Global Biotechnology industry.

( Industry Median: -71.50 vs. ARIA: -140.67 )
ARIA' s 10-Year Net-margin (%) Range
Min: -493975   Max: 194.03
Current: -140.67

-493975
194.03
ROE (%) -176.80
ARIA's ROE (%) is ranked lower than
90% of the 754 Companies
in the Global Biotechnology industry.

( Industry Median: -27.51 vs. ARIA: -176.80 )
ARIA' s 10-Year ROE (%) Range
Min: -523.41   Max: 93.23
Current: -176.8

-523.41
93.23
ROA (%) -33.01
ARIA's ROA (%) is ranked lower than
59% of the 832 Companies
in the Global Biotechnology industry.

( Industry Median: -23.16 vs. ARIA: -33.01 )
ARIA' s 10-Year ROA (%) Range
Min: -120.13   Max: 92.14
Current: -33.01

-120.13
92.14
ROC (Joel Greenblatt) (%) -90.18
ARIA's ROC (Joel Greenblatt) (%) is ranked higher than
61% of the 805 Companies
in the Global Biotechnology industry.

( Industry Median: -344.23 vs. ARIA: -90.18 )
ARIA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2869.58   Max: 1329.95
Current: -90.18

-2869.58
1329.95
Revenue Growth (3Y)(%) 43.40
ARIA's Revenue Growth (3Y)(%) is ranked higher than
90% of the 396 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. ARIA: 43.40 )
ARIA' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 214.8
Current: 43.4

0
214.8
EBITDA Growth (3Y)(%) -4.70
ARIA's EBITDA Growth (3Y)(%) is ranked higher than
50% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: -4.70 vs. ARIA: -4.70 )
ARIA' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -16.2   Max: 36.2
Current: -4.7

-16.2
36.2
EPS Growth (3Y)(%) -2.20
ARIA's EPS Growth (3Y)(%) is ranked higher than
55% of the 408 Companies
in the Global Biotechnology industry.

( Industry Median: -7.70 vs. ARIA: -2.20 )
ARIA' s 10-Year EPS Growth (3Y)(%) Range
Min: -18.1   Max: 24.7
Current: -2.2

-18.1
24.7
» ARIA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

ARIA Guru Trades in Q2 2014

George Soros 1,000,000 sh (+100.00%)
Jim Simons 4,399,981 sh (+95.66%)
Louis Moore Bacon 300,000 sh (unchged)
Chuck Royce 480,602 sh (-6.97%)
» More
Q3 2014

ARIA Guru Trades in Q3 2014

Stanley Druckenmiller 1,645,000 sh (New)
Louis Moore Bacon 300,000 sh (unchged)
Chuck Royce 440,602 sh (-8.32%)
Jim Simons 1,252,681 sh (-71.53%)
George Soros 150,000 sh (-85.00%)
» More
Q4 2014

ARIA Guru Trades in Q4 2014

Paul Tudor Jones 27,227 sh (New)
Louis Moore Bacon 300,000 sh (unchged)
Chuck Royce 440,602 sh (unchged)
Stanley Druckenmiller Sold Out
George Soros Sold Out
Jim Simons 281,381 sh (-77.54%)
» More
Q1 2015

ARIA Guru Trades in Q1 2015

Joel Greenblatt 16,344 sh (New)
Michael Price 550,000 sh (New)
Jim Simons 2,675,481 sh (+850.84%)
Chuck Royce 375,352 sh (-14.81%)
Paul Tudor Jones 15,595 sh (-42.72%)
» More
» Details

Insider Trades

Latest Guru Trades with ARIA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 45.50
ARIA's P/B is ranked lower than
145% of the 713 Companies
in the Global Biotechnology industry.

( Industry Median: 3.32 vs. ARIA: 45.50 )
Ranked among companies with meaningful P/B only.
ARIA' s 10-Year P/B Range
Min: 1.69   Max: 222.33
Current: 45.5

1.69
222.33
P/S 14.40
ARIA's P/S is ranked lower than
76% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: 7.28 vs. ARIA: 14.40 )
Ranked among companies with meaningful P/S only.
ARIA' s 10-Year P/S Range
Min: 1.71   Max: 1334
Current: 14.4

1.71
1334
Current Ratio 3.97
ARIA's Current Ratio is ranked lower than
53% of the 805 Companies
in the Global Biotechnology industry.

( Industry Median: 4.36 vs. ARIA: 3.97 )
Ranked among companies with meaningful Current Ratio only.
ARIA' s 10-Year Current Ratio Range
Min: 0.62   Max: 15.1
Current: 3.97

0.62
15.1
Quick Ratio 3.96
ARIA's Quick Ratio is ranked lower than
51% of the 805 Companies
in the Global Biotechnology industry.

( Industry Median: 4.07 vs. ARIA: 3.96 )
Ranked among companies with meaningful Quick Ratio only.
ARIA' s 10-Year Quick Ratio Range
Min: 0.52   Max: 14.95
Current: 3.96

0.52
14.95
Days Inventory 63.95
ARIA's Days Inventory is ranked higher than
72% of the 404 Companies
in the Global Biotechnology industry.

( Industry Median: 115.80 vs. ARIA: 63.95 )
Ranked among companies with meaningful Days Inventory only.
ARIA' s 10-Year Days Inventory Range
Min: 8.07   Max: 321.09
Current: 63.95

8.07
321.09
Days Sales Outstanding 34.97
ARIA's Days Sales Outstanding is ranked higher than
76% of the 556 Companies
in the Global Biotechnology industry.

( Industry Median: 61.41 vs. ARIA: 34.97 )
Ranked among companies with meaningful Days Sales Outstanding only.
ARIA' s 10-Year Days Sales Outstanding Range
Min: 0.49   Max: 287.59
Current: 34.97

0.49
287.59

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 44.80
ARIA's Price/Tangible Book is ranked lower than
155% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ARIA: 44.80 )
Ranked among companies with meaningful Price/Tangible Book only.
ARIA' s 10-Year Price/Tangible Book Range
Min: 1.64   Max: 1133
Current: 44.8

1.64
1133
Price/Median PS Value 0.20
ARIA's Price/Median PS Value is ranked higher than
97% of the 545 Companies
in the Global Biotechnology industry.

( Industry Median: 1.00 vs. ARIA: 0.20 )
Ranked among companies with meaningful Price/Median PS Value only.
ARIA' s 10-Year Price/Median PS Value Range
Min: 0.02   Max: 17.43
Current: 0.2

0.02
17.43
Earnings Yield (Greenblatt) -9.10
ARIA's Earnings Yield (Greenblatt) is ranked lower than
71% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: -4.40 vs. ARIA: -9.10 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
ARIA' s 10-Year Earnings Yield (Greenblatt) Range
Min: -9.2   Max: 42.7
Current: -9.1

-9.2
42.7

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:APS.Germany, ARIA.Switzerland,
Ariad Pharmaceuticals Inc was organized as a Delaware corporation in April 1991. It is an oncology company. The Company is focused on discovery and development of breakthrough medicines to treat cancers by regulating cell signaling with small molecules. The Company's first approved cancer medicine, Iclusig (ponatinib), and its product candidates, AP26113 and ridaforolimus, were discovered internally by its scientists based on the expertise in computational and structure-based drug design. AP26113 is an investigational inhibitor of anaplastic lymphoma kinase, or ALK. In non-clinical studies, AP26113 also demonstrated that it can inhibit epidermal growth factor receptor, or EGFR, and c-ros oncogene-1, or ROS1. . Iclusig and its drug candidates and preclinical compounds are small molecules that can be readily synthesized by processes that they have developed. The Company do not own or operate manufacturing facilities for the production of clinical or commercial quantities of Iclusig or its product candidates. The company's competitors includes pharmaceutical and biotechnology companies such as Amgen Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, the Roche Group, GlaxoSmithKline plc, Johnson & Johnson, Merck, Merck KGaA, Novartis AG, Pfizer, Inc., Sanofi-Aventis, Takeda Pharmaceutical Co., Ltd., and Teva Pharmaceutical Industries Ltd.Inc.
» More Articles for NAS:ARIA

Headlines

Articles On GuruFocus.com
Michael Price Invests in 11 Companies in First Quarter May 19 2015 
Sarah Ketterer of Causeway Capital's Answers to GuruFocus Q&A Apr 07 2014 
Weekly CEO Sells Highlight: U.S. Bancorp, Restoration Hardware Holdings Inc, Ariad Pharmaceuticals, Jul 20 2013 
Daniel Loeb's Top Three Increases of the First Quarter May 24 2013 
comment on ARIA Mar 15 2013 
comment on ARIA Mar 15 2013 
comment on ARIA May 16 2012 
Weekly CFO Sales Highlight: WWWW, FIO, CRIS, ARIA, VOG, APKT Apr 22 2012 
3 Biotech Stocks To Consider Buying Right Now Jan 10 2012 
ARIAD Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 15 2011 

More From Other Websites
ARIAD Announces Data Presentations at the European Hematology Association (EHA) Congress May 22 2015
ARIAD Announces Data Presentations at the European Hematology Association (EHA) Congress May 22 2015
ARIAD to Present at the Jefferies 2015 Global Healthcare Conference May 21 2015
ARIAD to Present at the Jefferies 2015 Global Healthcare Conference May 21 2015
Michael Price Invests in 11 Companies in First Quarter May 19 2015
ARIAD PHARMACEUTICALS INC Financials May 16 2015
Stifel Talks 5 Biotech Stocks May 14 2015
ARIAD Announces Data Presentations at the 2015 ASCO Annual Meeting May 14 2015
10-Q for ARIAD Pharmaceuticals, Inc. May 11 2015
These biotech names are ripe for mergers: Analysts May 10 2015
ARIAD PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report May 08 2015
ARIAD (ARIA) Q1 Loss Wider than Estimates; Iclusig Grows - Analyst Blog May 08 2015
ARIAD (ARIA) Q1 Loss a Penny Wider than Expected - Tale of the Tape May 07 2015
ARIAD Pharmaceuticals Inc Earnings Call scheduled for 8:30 am ET today May 07 2015
Ariad reports 1Q loss May 07 2015
Ariad reports 1Q loss May 07 2015
ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... May 07 2015
ARIAD Reports First Quarter 2015 Financial Results and Progress on Strategic Objectives May 07 2015
Q1 2015 ARIAD Pharmaceuticals Inc Earnings Release - Before Market Open May 07 2015
Biotech takeover targets May 06 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK